BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Celgene (CELG) Acquisition of The Leukemia & Lymphoma Society Partner, Avila Therapeutics, Significant Advance for Novel Blood Cancer Therapy


1/27/2012 10:59:41 AM

WHITE PLAINS, N.Y., Jan. 26, 2012 /PRNewswire/ -- Thanks to funding from The Leukemia & Lymphoma Society (LLS), Avila Therapeutics, Inc. has been testing AVL-292, a highly selective Bruton's tyrosine kinsase (Btk) inhibitor in Phase I clinical trials.

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO )

LLS's goal in establishing its collaboration with Avila in 2010 was to help accelerate the development of AVL-292 as a treatment for patients with B-cell blood cancers. Today's announcement that Celgene Corporation has acquired Avila Therapeutics is an important advance in the development of AVL-292 and for the patients who stand to benefit from it.

"We've been impressed by the speed with which Avila has been able to advance the Btk covalent drug program to this point in development, as patients with B-cell cancers need new treatment options," said Louis DeGennaro, Ph.D., LLS's chief mission officer. "Today's announcement placing these important resources within Celgene's successful development program gives us tremendous confidence that the full potential of this impactful research will be met. LLS's goal is to bridge the drug development gap and bring promising therapies to the next level of funding and today's news is a perfect example of this goal in action."

"Celgene is dedicated to working closely with organizations like the LLS, as we accelerate the development of promising new therapies for patients in need," said Joseph Camardo, M.D., Celgene's senior vice president, Global Medical Affairs. "We are very excited at the promise that AVL-292 holds for patients with difficult to treat blood cancers."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

Andrea Greif
(914) 821-8958
andrea.greif@lls.org

SOURCE The Leukemia & Lymphoma Society



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES